DSGN — Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$679.0M

P/E Ratio

-9.04

Beta

1.63

52-Week Range

2.6-11.23

Dividend Yield

$0.00

CEO

Pratik Shah

Employees

56

IPO Date

Mar 29, 2021

Exchange

NASDAQ